Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Rev Med Chil ; 136(6): 775-82, 2008 Jun.
Artigo em Espanhol | MEDLINE | ID: mdl-18769836

RESUMO

Results of numerous epidemiologic studies indicate that elevated serum cholesterol, especially the LDL fraction, is a major cause of coronary heart disease (CHD). Epidemiologic and angiographic evidence from primary and secondary prevention studies involving several HMG-CoA reductase inhibitors (statins) indicate that decreasing elevated serum cholesterol concentration (specifically LDL-cholesterol) can reduce the incidence of CHD and/or progression of atherosclerosis and results in a decrease in associated morbidity and mortality. It has been estimated that each 1% reduction in LDL-cholesterol concentration may result in a 1% decrease in the incidence of CHD. Furthermore, an analysis of pooled data from primary and secondary prevention studies found that treatment with a statin for a median duration of 5.4 years was associated with a 31% and 21% reduction in the risk of major coronary events and total mortality, respectively. This paper deals with the pharmacology of statins, specially with the pleiotropic effects of these drugs.


Assuntos
Anticolesterolemiantes/farmacologia , Antioxidantes/farmacologia , Aterosclerose/tratamento farmacológico , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Atorvastatina , Endotélio Vascular/efeitos dos fármacos , Ácidos Graxos Monoinsaturados/farmacologia , Fluorbenzenos/farmacologia , Fluvastatina , Ácidos Heptanoicos/farmacologia , Humanos , Hipercolesterolemia/tratamento farmacológico , Indóis/farmacologia , Lovastatina/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Pravastatina/farmacologia , Pirimidinas/farmacologia , Pirróis/farmacologia , Rosuvastatina Cálcica , Sulfonamidas/farmacologia
2.
Rev. méd. Chile ; 136(6): 775-782, jun. 2008. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-490765

RESUMO

Results of numerous epidemiologic studies indicate that elevated serum cholesterol, especially the LDL fraction, is a major cause of coronary heart disease (CHD). Epidemiologic and angiographic evidence from primary and secondary prevention studies involving several HMG-CoA reducíase inhibitors (statins) indicate that decreasing elevated serum cholesterol concentration (specifically LDL-cholesterol) can reduce the incidence of CHD and/or progression of atherosclerosis and results in a decrease in associated morbidity and mortality. It has been estimated that each 1 percent reduction in LDL-cholesterol concentration may result in a 1 percent decrease in the incidence of CHD. Furthermore, an analysis of pooled data from primary and secondary prevention studies found that treatment with a statin for a median duration of 5.4 years was associated with a 31 percent and 21 percent reduction in the risk of major coronary events and total mortality, respectively. This paper deals with the pharmacology of statins, specially with the pleiotropic effects ofthese drugs.


Assuntos
Humanos , Anticolesterolemiantes/farmacologia , Antioxidantes/farmacologia , Aterosclerose/tratamento farmacológico , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Endotélio Vascular/efeitos dos fármacos , Ácidos Graxos Monoinsaturados/farmacologia , Fluorbenzenos/farmacologia , Ácidos Heptanoicos/farmacologia , Hipercolesterolemia/tratamento farmacológico , Indóis/farmacologia , Lovastatina/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Pravastatina/farmacologia , Pirimidinas/farmacologia , Pirróis/farmacologia , Sulfonamidas/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA